# US 11,999,775 B2 · VEGF-binding protein for blockade of angiogenesis > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,999,775 B2 - Document ID: US11999775B2 - Status: Granted - Kind: B2 - Application number: 16/291,829 - Filed: 2019-03-04 - Published: 2019-09-26 - Granted: 2024-06-04 - Earliest claimed: 2011-08-19 - Assignees: Children's Medical Center Corporation; The General Hospital Corporation; President and Fellows of Harvard College - Applicants: Children's Medical Center Corporation; The General Hospital Corporation; President and Fellows of Harvard College - Inventors: Bob Carter; Jeng-Shin Lee; Szofia S. Bullain; Richard C. Mulligan - Web page: https://patentgrep.com/patent/US11999775B2 ## CPC - C07K 14/71: for growth factors; for growth regulators - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - A61P 35/00: Antineoplastic agents - C07K 14/475: Growth factors; Growth regulators - C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} - A61K 35/42: Respiratory system, e.g. lungs, bronchi or lung cells - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 39/001109: {Vascular endothelial growth factor receptors [VEGFR]} - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones} - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein. ## Claims ### Claim 1 A method of treating an angiogenic disease or disorder, comprising administering to a subject in need thereof a vector comprising a polynucleotide encoding a chimeric VEGF-binding protein comprising the amino acid sequence of SEQ ID NO: 3. ### Claim 2 (depends on 1) The method according to claim 1, wherein the vector is an expression vector that is compatible with a protein expression system using host cells selected from the group consisting of: mammalian cells, insect cells, yeast cells, bacterial cells, and plant cells. ### Claim 3 (depends on 1) The method of claim 1, wherein the vector is a viral vector. ### Claim 4 (depends on 3) The method of claim 3, wherein the viral vector is an adeno-associated virus (AAV) vector. ### Claim 5 (depends on 3) The method of claim 3, wherein the viral vector is a lentivirus vector. ### Claim 6 (depends on 1) The method of claim 1, wherein the subject has a cancer. ### Claim 7 (depends on 6) The method of claim 6, wherein the cancer is a cancer selected from the group consisting of: glioma, bladder cancer, breast cancer, colon cancer, melanoma, liver cancer, lung cancer, ovarian cancer, prostate cancer, renal cell carcinoma, hemangioma, and astrocytoma. ### Claim 8 (depends on 7) The method of claim 7, wherein the cancer is lung cancer. ### Claim 9 (depends on 1) The method of claim 1, wherein the subject has age-related macular degeneration. ### Claim 10 (depends on 1) The method of claim 1, wherein the subject has wet macular degeneration. ### Claim 11 (depends on 1) The method of claim 1, wherein the subject has diabetic retinopathy. ### Claim 12 (depends on 1) The method of claim 1, wherein the subject has an abnormal build-up or growth of blood vessels in the skin. ### Claim 13 (depends on 1) The method of claim 1, wherein the subject has a hemangioma. ### Claim 14 (depends on 1) The method of claim 1, wherein the subject has endometriosis. ### Claim 15 A method of reducing blood vessel formation in a tumor in a subject, the method comprising administering to a subject in need thereof a vector comprising a polynucleotide encoding a chimeric VEGF-binding protein comprising the amino acid sequence of SEQ ID NO: 3. ### Claim 16 (depends on 15) The method of claim 15, wherein the administering is performed using intratumoral or peritumoral administration. ### Claim 17 (depends on 15) The method of claim 15, wherein the tumor is a lung cancer tumor.